Rep Kim Schrier, MD, (D-Wash.), said on X yesterday that some of the newly appointed ACIP replacements are anti-vaccine ...

Vepdegestrant significantly improved outcomes for certain patients with ER-positive, HER2-negative advanced breast cancer ...

Roche has secured a new FDA approval ... negative following a pathologist’s biopsy review. Enhertu received an FDA nod in HER2-ultralow breast cancer in late January, its seventh agency approval ...

The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which identifies patients with HR–positive, HER2-ultralow metastatic breast ...

Basel, 31 January 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved a ... Endocrine Therapy in Metastatic Breast Cancer, New ...

The PATHWAY HER2 (4B5) test, the first and only FDA ... cancer patients. HER2 interpretation in breast cancer is evolving. With the introduction of HER2-low and now HER2-ultralow classifications ...

Basel, 31 October 2024 - Roche (SIX: RO, ROG; OTCQX ... locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...

Early, comprehensive biomarker testing with an FDA-approved test, such as Foundation Medicine's FoundationOne ... receptor-positive breast cancer. Oncology (Williston Park). 2012;26(8):688-94,696. [6] ...

The United States Food and Drug Administration (FDA) has approved Roche’s Itovebi ... such as Foundation Medicine’s FoundationOne Liquid CDx, can help identify people with HR-positive, HER2-negative ...

Breast cancer is a group of abnormal cells growing uncontrolably, starting in the breast tissue. Nearly all cases of breast cancer affect women, but men can get ... FDA’s NDA and PMA review ...